Fenwick Represents Chinook Therapeutics in Merger with Aduro Biotech

Fenwick is representing Chinook Therapeutics, Inc., a privately held clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, in its pending merger with Aduro Biotech, Inc. (NASDAQ: ADRO).

Aduro will acquire all of the outstanding capital stock of Chinook in exchange for shares of Aduro common stock representing approximately 50 percent of Aduro’s outstanding common stock immediately following completion of the transaction. The closing of the merger is expected to occur in the second half of 2020.

More information can be obtained from the company’s announcement.

The Fenwick transaction team includes corporate partners Effie Toshav, Ethan Skerry, Robert Freedman and Amanda Rose, and associates Maureen Montgomery, Kristin Esannason, Ryan Mitteness, Trevor Lynch, Alice Lin, Kristen Nicol and Jennifer Wu; executive compensation and employee benefits partner Matthew Cantor and associate Corinne Nhaissi; intellectual property and technology transaction partners Stefano Quintini and Antonia Sequeira, counsel Amy Klann, and associates Sophia Chen, Jennifer Yoon, Arjun Ravi, Russell Wong and Sang Kwon; tax partner William Skinner and associate Ora Grinberg.